Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo

Nanomedicine. 2016 Jul;12(5):1185-92. doi: 10.1016/j.nano.2016.01.021. Epub 2016 Mar 10.


In this work we have tested the potential antiviral activity of silver nanoparticles formulated as Argovit™ against Rift Valley fever virus (RVFV). The antiviral activity of Argovit was tested on Vero cell cultures and in type-I interferon receptor deficient mice (IFNAR (-/-) mice) by two different approaches: (i) different dilutions of Argovit were added to previously infected cells or administrated to animals infected with a lethal dose of virus; (ii) virus was pre-incubated with different dilutions of Argovit before inoculation in mice or cells. Though the ability of silver nanoparticles to control an ongoing RVFV infection in the conditions tested was limited, the incubation of virus with Argovit before the infection led to a reduction of the infectivity titers both in vitro and in vivo. These results reveal the potential application of silver nanoparticles to control the infectivity of RVFV, which is an important zoonotic pathogen.

Keywords: Antivirals; In vivo infection; Rift Valley fever virus; Silver nanoparticles.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Mice
  • Nanoparticles / therapeutic use*
  • Rift Valley Fever / prevention & control
  • Rift Valley fever virus / drug effects*
  • Rift Valley fever virus / pathogenicity
  • Silver / therapeutic use*


  • Antiviral Agents
  • Silver